Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hodgkin Disease × Radiotherapy × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

OTHER 50 NETWORK 8 NIH 7 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 32 Carcinoma, Non-Small-Cell Lung 21 Head and Neck Neoplasms 15 Brain Neoplasms 11 Squamous Cell Carcinoma of Head and Neck 10 Glioma 9 Lung Neoplasms 8 Breast Neoplasms 8 Rectal Neoplasms 7 Prostatic Neoplasms 6 Neoplasms 6 Carcinoma, Squamous Cell 6 Astrocytoma 6 Carcinoma 4 Neoplasm Metastasis 3 Mucositis 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Stomatitis 2 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Lymphoma 2 Leukemia 2 Laryngeal Diseases 2 Gliosarcoma 2 Adenocarcinoma Of Esophagus 2 Adenocarcinoma 2 Xerostomia 1 Uterine Cervical Neoplasms 1

Interventions

Brentuximab Vedotin 20 pembrolizumab 11 Vinblastine 6 Doxorubicin 6 Dacarbazine 6 plerixafor 4 fludarabine 4 Nivolumab 4 Cyclophosphamide 4 Azacitidine 4 Melphalan 3 Granulocyte Colony-Stimulating Factor 3 Gemcitabine 3 Filgrastim 3 Etoposide 3 Busulfan 3 Bleomycin 3 pegfilgrastim 2 mocetinostat 2 givinostat hydrochloride 2 givinostat 2 fludarabine phosphate 2 cc-486 2 abexinostat 2 TPI-287 2 Panobinostat 2 Mycophenolic Acid 2 Leukapheresis 2 Clofarabine 2 Carmustine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡